Nanotechnology approaches for delivery of cytochrome P450 substrates in HIV treatment

Yuqing Gong, Pallabita Chowdhury, Prashanth K.B. Nagesh, Theodore Cory, Chelsea Dezfuli, Sunitha Kodidela, Ajay Singh, Murali Yallapu, Santosh Kumar

Research output: Contribution to journalReview article

Abstract

Introduction: Antiretroviral therapy (ART) has led to a significant reduction in HIV-1 morbidity and mortality. Many antiretroviral drugs (ARVs) are metabolized by cytochrome P450 (CYP) pathway, and the majority of these drugs are also either CYP inhibitors or inducers and few possess both activities. These CYP substrates, when used for HIV treatment in the conventional dosage form, have limitations such as low systemic bioavailability, potential drug–drug interactions, and short half-lives. Thus, an alternative mode of delivery is needed in contrast to conventional ARVs. Areas covered: In this review, we summarized the limitations of conventional ARVs in HIV treatment, especially for ARVs which are CYP substrates. We also discussed the preclinical and clinical studies using the nanotechnology strategy to overcome the limitations of these CYP substrates. The preclinical studies and clinical studies published from 2000 to February 2019 were discussed. Expert opinion: Since preclinical and clinical studies for prevention and treatment of HIV using nanotechnology approaches have shown considerable promise in recent years, nanotechnology could become an alternative strategy for daily oral therapy as a future treatment.

Original languageEnglish (US)
Pages (from-to)869-882
Number of pages14
JournalExpert Opinion on Drug Delivery
Volume16
Issue number8
DOIs
StatePublished - Jan 1 2019

Fingerprint

Nanotechnology
Cytochrome P-450 Enzyme System
HIV
Pharmaceutical Preparations
Dosage Forms
Expert Testimony
Drug Interactions
Biological Availability
HIV-1
Morbidity
Mortality
Therapeutics
Clinical Studies

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Nanotechnology approaches for delivery of cytochrome P450 substrates in HIV treatment. / Gong, Yuqing; Chowdhury, Pallabita; Nagesh, Prashanth K.B.; Cory, Theodore; Dezfuli, Chelsea; Kodidela, Sunitha; Singh, Ajay; Yallapu, Murali; Kumar, Santosh.

In: Expert Opinion on Drug Delivery, Vol. 16, No. 8, 01.01.2019, p. 869-882.

Research output: Contribution to journalReview article

Gong, Yuqing ; Chowdhury, Pallabita ; Nagesh, Prashanth K.B. ; Cory, Theodore ; Dezfuli, Chelsea ; Kodidela, Sunitha ; Singh, Ajay ; Yallapu, Murali ; Kumar, Santosh. / Nanotechnology approaches for delivery of cytochrome P450 substrates in HIV treatment. In: Expert Opinion on Drug Delivery. 2019 ; Vol. 16, No. 8. pp. 869-882.
@article{1238b188c5334e64bc361205336f2dae,
title = "Nanotechnology approaches for delivery of cytochrome P450 substrates in HIV treatment",
abstract = "Introduction: Antiretroviral therapy (ART) has led to a significant reduction in HIV-1 morbidity and mortality. Many antiretroviral drugs (ARVs) are metabolized by cytochrome P450 (CYP) pathway, and the majority of these drugs are also either CYP inhibitors or inducers and few possess both activities. These CYP substrates, when used for HIV treatment in the conventional dosage form, have limitations such as low systemic bioavailability, potential drug–drug interactions, and short half-lives. Thus, an alternative mode of delivery is needed in contrast to conventional ARVs. Areas covered: In this review, we summarized the limitations of conventional ARVs in HIV treatment, especially for ARVs which are CYP substrates. We also discussed the preclinical and clinical studies using the nanotechnology strategy to overcome the limitations of these CYP substrates. The preclinical studies and clinical studies published from 2000 to February 2019 were discussed. Expert opinion: Since preclinical and clinical studies for prevention and treatment of HIV using nanotechnology approaches have shown considerable promise in recent years, nanotechnology could become an alternative strategy for daily oral therapy as a future treatment.",
author = "Yuqing Gong and Pallabita Chowdhury and Nagesh, {Prashanth K.B.} and Theodore Cory and Chelsea Dezfuli and Sunitha Kodidela and Ajay Singh and Murali Yallapu and Santosh Kumar",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/17425247.2019.1646725",
language = "English (US)",
volume = "16",
pages = "869--882",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Nanotechnology approaches for delivery of cytochrome P450 substrates in HIV treatment

AU - Gong, Yuqing

AU - Chowdhury, Pallabita

AU - Nagesh, Prashanth K.B.

AU - Cory, Theodore

AU - Dezfuli, Chelsea

AU - Kodidela, Sunitha

AU - Singh, Ajay

AU - Yallapu, Murali

AU - Kumar, Santosh

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Antiretroviral therapy (ART) has led to a significant reduction in HIV-1 morbidity and mortality. Many antiretroviral drugs (ARVs) are metabolized by cytochrome P450 (CYP) pathway, and the majority of these drugs are also either CYP inhibitors or inducers and few possess both activities. These CYP substrates, when used for HIV treatment in the conventional dosage form, have limitations such as low systemic bioavailability, potential drug–drug interactions, and short half-lives. Thus, an alternative mode of delivery is needed in contrast to conventional ARVs. Areas covered: In this review, we summarized the limitations of conventional ARVs in HIV treatment, especially for ARVs which are CYP substrates. We also discussed the preclinical and clinical studies using the nanotechnology strategy to overcome the limitations of these CYP substrates. The preclinical studies and clinical studies published from 2000 to February 2019 were discussed. Expert opinion: Since preclinical and clinical studies for prevention and treatment of HIV using nanotechnology approaches have shown considerable promise in recent years, nanotechnology could become an alternative strategy for daily oral therapy as a future treatment.

AB - Introduction: Antiretroviral therapy (ART) has led to a significant reduction in HIV-1 morbidity and mortality. Many antiretroviral drugs (ARVs) are metabolized by cytochrome P450 (CYP) pathway, and the majority of these drugs are also either CYP inhibitors or inducers and few possess both activities. These CYP substrates, when used for HIV treatment in the conventional dosage form, have limitations such as low systemic bioavailability, potential drug–drug interactions, and short half-lives. Thus, an alternative mode of delivery is needed in contrast to conventional ARVs. Areas covered: In this review, we summarized the limitations of conventional ARVs in HIV treatment, especially for ARVs which are CYP substrates. We also discussed the preclinical and clinical studies using the nanotechnology strategy to overcome the limitations of these CYP substrates. The preclinical studies and clinical studies published from 2000 to February 2019 were discussed. Expert opinion: Since preclinical and clinical studies for prevention and treatment of HIV using nanotechnology approaches have shown considerable promise in recent years, nanotechnology could become an alternative strategy for daily oral therapy as a future treatment.

UR - http://www.scopus.com/inward/record.url?scp=85070461325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070461325&partnerID=8YFLogxK

U2 - 10.1080/17425247.2019.1646725

DO - 10.1080/17425247.2019.1646725

M3 - Review article

VL - 16

SP - 869

EP - 882

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 8

ER -